News | April 12, 2026
C4 Therapeutics and Roche launch bold push into next-generation cancer drug modality
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
IntraSight Plus enables confident decision-making and better patient care,” Philips said, emphasizing efficiency, simplicity, and precision
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Designed for intense clinical environments, Rembra can handle up to 270 exams per day
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
Subscribe To Our Newsletter & Stay Updated
